 COGNATE is an acute, confirmatory prospective, multi-center study designed to gather data on Brady and CRT-P indicated patients, with no restrictions on the typebrand of leads. This study will enroll up to 80 patients in up to 12 centers. Total duration of the study is expected to be 9 months. 